U.S. to widen Covid antiviral pill distribution
President Joe Biden’s administration is aiming to expand access to Covid-19 oral antiviral treatments like Pfizer‘s Paxlovid by doubling the number of locations at which they are available, the White House said on Tuesday.
Pharmacies participating in the federal pharmacy program for distributing antiviral treatments will be able to order the free treatments directly from the U.S. government starting this week.
Currently, the pharmacies were dependent on states to obtain the pills. The government sends the treatments to select pharmacies, as well as directly to states and community centers. Under the current system, the treatments are available in around 20,000 locations.
“There’s more room to save more lives by getting this medication to more people,” a senior administration official told reporters on a press call.
The administration expects to increase their direct distribution to over 30,000 locations soon and reach 40,000 sites over the coming weeks, the official said.
Demand for Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions.
Paxlovid was expected to be a major tool in the fight against Covid after it reduced hospitalizations or deaths in high-risk patients by around 90% in a clinical trial.
The United States has agreed to buy up to 20 million pills at around $530 a course and Pfizer is on pace to produce 3.5 million courses earmarked for U.S. use by the end of April.
Through the first half of April, U.S. data shows it has distributed around 1.5 million courses and that pharmacies still have over 500,000 available.
The government also plans to roll out more federally supported test sites as part of its “Test to Treat” initiative that allows Americans to get tested for Covid-19 at a pharmacy and receive free pills if they test positive.
There are currently 2,200 such sites and the White House expects an additional 10,000 to come online right away.
The administration also aims to boost patient and provider awareness through public education campaigns.